6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
below	IN	below	below	below	N	O
or	CC	or	or	or	N	O
elsewhere	RB	elsewhere	elsewhere	elsewher	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
prescribing	NN	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
:	:	:	:	:	N	O

Risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
Thyroid	NNP	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
Tumors	NNPS	tumors	tumor	tumor	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O

Acute	NNP	acute	acute	acut	N	B-AdverseReaction
Pancreatitis	NNP	pancreatitis	pancreatitis	pancreat	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O

Hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
with	IN	with	with	with	N	O
Concomitant	NNP	concomitant	concomitant	concomit	N	O
Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
Secretagogues	NNP	secretagogues	secretagogues	secretagogu	N	O
or	CC	or	or	or	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
Impairment	NNP	impairment	impairment	impair	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
and	CC	and	and	and	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
influenza	NN	influenza	influenza	influenza	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
GlaxoSmithKline	NNP	glaxosmithkline	glaxosmithkline	glaxosmithklin	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
888	CD	888	888	888	N	O
-	:	-	-	-	N	O
825	CD	825	825	825	N	O
-	:	-	-	-	N	O
5249	CD	5249	5249	5249	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	NN	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O

The	DT	the	the	the	N	O
data	NN	data	data	data	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
are	VBP	are	are	are	N	O
derived	VBN	derived	derived	deriv	N	O
from	IN	from	from	from	N	O
4	CD	4	4	4	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
was	VBD	was	wa	wa	N	O
used	VBN	used	used	use	N	O
as	IN	as	a	as	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
in	IN	in	in	in	N	O
1	CD	1	1	1	N	O
trial	NN	trial	trial	trial	N	O
and	CC	and	and	and	N	O
as	IN	as	a	as	N	O
add	JJ	add	add	add	Y	O
-	:	-	-	-	N	O
on	IN	on	on	on	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
3	CD	3	3	3	N	O
trials	NNS	trials	trial	trial	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
data	NNS	data	data	data	N	O
reflect	VBP	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
of	IN	of	of	of	N	O
923	CD	923	923	923	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
of	IN	of	of	of	N	O
93	CD	93	93	93	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
participants	NNS	participants	participant	particip	N	O
was	VBD	was	wa	wa	N	O
55	CD	55	55	55	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
participants	NNS	participants	participant	particip	N	O
were	VBD	were	were	were	N	O
75	CD	75	75	75	N	O
years	NNS	years	year	year	N	O
or	CC	or	or	or	N	O
older	JJR	older	older	older	N	O
and	CC	and	and	and	N	O
53%	CD	53%	53%	53%	N	O
of	IN	of	of	of	N	O
participants	NNS	participants	participant	particip	N	O
were	VBD	were	were	were	N	O
male	JJ	male	male	male	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
studies	NNS	studies	study	studi	N	O
was	VBD	was	wa	wa	N	O
48%	CD	48%	48%	48%	N	O
white	JJ	white	white	white	N	O
,	,	,	,	,	N	O
13%	CD	13%	13%	13%	N	O
African	JJ	african	african	african	N	O
African	JJ	african	african	african	N	O
American	NNP	american	american	american	N	O
,	,	,	,	,	N	O
7%	CD	7%	7%	7%	N	O
Asian	JJ	asian	asian	asian	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
29%	CD	29%	29%	29%	N	O
Hispanic	NNP	hispanic	hispanic	hispan	N	O
Latino	NNP	latino	latino	latino	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
had	VBD	had	had	had	N	O
type	JJ	type	type	type	N	O
2	CD	2	2	2	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
for	IN	for	for	for	N	O
an	DT	an	an	an	N	O
average	NN	average	average	averag	N	O
of	IN	of	of	of	N	O
7	CD	7	7	7	N	O
years	NNS	years	year	year	N	O
and	CC	and	and	and	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
HbA1c	NNP	hba1c	hba1c	hba1c	Y	O
of	IN	of	of	of	N	O
8.1%	CD	8.1%	8.1%	8.1%	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
17%	CD	17%	17%	17%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
studies	NNS	studies	study	studi	N	O
reported	VBD	reported	reported	report	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	O
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	O
and	CC	and	and	and	N	O
4%	CD	4%	4%	4%	N	O
reported	VBD	reported	reported	report	N	O
retinopathy	NN	retinopathy	retinopathy	retinopathi	Y	O
.	.	.	.	.	N	O

Baseline	NNP	baseline	baseline	baselin	N	O
estimated	VBD	estimated	estimated	estim	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
was	VBD	was	wa	wa	N	O
normal	JJ	normal	normal	normal	N	O
or	CC	or	or	or	N	O
mildly	RB	mildly	mildly	mildli	N	O
impaired	JJ	impaired	impaired	impair	N	O
(	(	(	(	(	N	O
eGFR	JJ	egfr	egfr	egfr	N	O
60	CD	60	60	60	N	O
mL	NN	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
91%	CD	91%	91%	91%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
study	NN	study	study	studi	N	O
population	NN	population	population	popul	N	O
and	CC	and	and	and	N	O
moderately	RB	moderately	moderately	moder	N	O
impaired	JJ	impaired	impaired	impair	N	O
(	(	(	(	(	N	O
eGFR	JJ	egfr	egfr	egfr	N	O
30	CD	30	30	30	N	O
to	TO	to	to	to	N	O
60	CD	60	60	60	N	O
mL	NNS	ml	ml	ml	N	O
min	RB	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NNS	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
9%	CD	9%	9%	9%	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
shows	NNS	shows	show	show	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
excluding	VBG	excluding	excluding	exclud	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	O
present	JJ	present	present	present	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
more	JJR	more	more	more	N	O
commonly	RB	commonly	commonly	commonli	N	O
on	IN	on	on	on	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
than	IN	than	than	than	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
a	DT	a	a	a	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
468	CD	468	468	468	N	O
)	)	)	)	)	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
923	CD	923	923	923	N	O
)	)	)	)	)	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
13.0	CD	13.0	13.0	13.0	N	O
14.2	CD	14.2	14.2	14.2	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
10.5	CD	10.5	10.5	10.5	N	O
13.1	CD	13.1	13.1	13.1	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
9.6	CD	9.6	9.6	9.6	N	O
11.1	CD	11.1	11.1	11.1	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactionb	VBD	reactionb	reactionb	reactionb	N	I-AdverseReaction
2.1	CD	2.1	2.1	2.1	N	O
10.5	CD	10.5	10.5	10.5	N	O

Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
6.2	CD	6.2	6.2	6.2	N	O
6.9	CD	6.9	6.9	6.9	N	O

Back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
5.8	CD	5.8	5.8	5.8	N	O
6.7	CD	6.7	6.7	6.7	N	O

Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
6.4	CD	6.4	6.4	6.4	N	O
6.6	CD	6.6	6.6	6.6	N	O

Sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
5.8	CD	5.8	5.8	5.8	N	O
6.2	CD	6.2	6.2	6.2	N	O

Influenza	NNP	influenza	influenza	influenza	Y	B-AdverseReaction
3.2	CD	3.2	3.2	3.2	N	O
5.2	CD	5.2	5.2	5.2	N	O

a	DT	a	a	a	N	O
Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBD	reported	reported	report	N	O
includes	VBZ	includes	includes	includ	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
glycemic	JJ	glycemic	glycemic	glycem	N	O
rescue	NN	rescue	rescue	rescu	N	O
medications	NNS	medications	medication	medic	N	O
which	WDT	which	which	which	N	O
included	VBD	included	included	includ	N	O
metformin	NN	metformin	metformin	metformin	N	O
(	(	(	(	(	N	O
17%	CD	17%	17%	17%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
10%	CD	10%	10%	10%	N	O
for	IN	for	for	for	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
insulin	NN	insulin	insulin	insulin	Y	O
(	(	(	(	(	N	O
24%	CD	24%	24%	24%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
14%	CD	14%	14%	14%	N	O
for	IN	for	for	for	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

b	NN	b	b	b	N	O
See	NNP	see	see	see	N	O
below	IN	below	below	below	N	O
for	IN	for	for	for	N	O
other	JJ	other	other	other	N	O
events	NNS	events	event	event	N	O
of	IN	of	of	of	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
reported	VBD	reported	reported	report	N	O
.	.	.	.	.	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

In	IN	in	in	in	N	O

the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
complaints	NNS	complaints	complaint	complaint	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
among	IN	among	among	among	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
(	(	(	(	(	N	O
39%	CD	39%	39%	39%	N	O
)	)	)	)	)	N	O
than	IN	than	than	than	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
33%	CD	33%	33%	33%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
to	TO	to	to	to	N	O
diarrhea	VB	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
and	CC	and	and	and	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
also	RB	also	also	also	N	O
occurred	VBD	occurred	occurred	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TANZEUM	NN	tanzeum	tanzeum	tanzeum	N	O
:	:	:	:	:	N	O
vomiting	NN	vomiting	vomiting	vomit	Y	B-AdverseReaction
(	(	(	(	(	N	O
2.6%	CD	2.6%	2.6%	2.6%	N	O
versus	NN	versus	versus	versu	N	O
4.2%	CD	4.2%	4.2%	4.2%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
versus	NN	versus	versus	versu	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
gastroesophageal	JJ	gastroesophageal	gastroesophageal	gastroesophag	N	B-AdverseReaction
reflux	NN	reflux	reflux	reflux	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
(	(	(	(	(	N	O
1.9%	CD	1.9%	1.9%	1.9%	N	O
versus	NN	versus	versus	versu	N	O
3.5%	CD	3.5%	3.5%	3.5%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
versus	NN	versus	versus	versu	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
dyspepsia	NN	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
(	(	(	(	(	N	O
2.8%	CD	2.8%	2.8%	2.8%	N	O
versus	NN	versus	versus	versu	N	O
3.4%	CD	3.4%	3.4%	3.4%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
versus	NN	versus	versus	versu	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Constipation	NNP	constipation	constipation	constip	Y	B-AdverseReaction
also	RB	also	also	also	N	O
contributed	VBD	contributed	contributed	contribut	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
frequently	RB	frequently	frequently	frequent	N	O
reported	VBN	reported	reported	report	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
group	NN	group	group	group	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
,	,	,	,	,	N	O
investigators	NNS	investigators	investigator	investig	N	O
graded	VBD	graded	graded	grade	N	O
the	DT	the	the	the	N	O
severity	NN	severity	severity	sever	N	O
of	IN	of	of	of	N	O
GI	NNP	gi	gi	gi	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
as	IN	as	a	as	N	O
"	JJ	"	"	"	N	O
mild	JJ	mild	mild	mild	N	B-Severity
"	NN	"	"	"	N	O
in	IN	in	in	in	N	O
56%	CD	56%	56%	56%	N	O
of	IN	of	of	of	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
"	JJ	"	"	"	N	O
moderate	JJ	moderate	moderate	moder	N	B-Severity
"	NN	"	"	"	N	O
in	IN	in	in	in	N	O
37%	CD	37%	37%	37%	N	O
of	IN	of	of	of	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
"	NNP	"	"	"	N	O
severe	JJ	severe	severe	sever	N	B-Severity
"	NN	"	"	"	N	O
in	IN	in	in	in	N	O
7%	CD	7%	7%	7%	N	O
of	IN	of	of	of	N	O
cases	NNS	cases	case	case	N	O
.	.	.	.	.	N	O

Discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
GI	NNP	gi	gi	gi	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
individuals	NNS	individuals	individual	individu	N	O
on	IN	on	on	on	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Injection	NNP	injection	injection	inject	Y	O
Site	NNP	site	site	site	N	O
Reactions	NNS	reactions	reaction	reaction	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
on	IN	on	on	on	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
(	(	(	(	(	N	O
18%	CD	18%	18%	18%	N	O
)	)	)	)	)	N	O
than	IN	than	than	than	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
term	NN	term	term	term	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
other	JJ	other	other	other	N	O
types	NNS	types	type	type	N	O
of	IN	of	of	of	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
also	RB	also	also	also	N	O
occurred	VBD	occurred	occurred	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
on	IN	on	on	on	N	O
TANZEUM	NN	tanzeum	tanzeum	tanzeum	N	O
:	:	:	:	:	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
(	(	(	(	(	N	O
1.9%	CD	1.9%	1.9%	1.9%	N	O
versus	NN	versus	versus	versu	N	O
2.1%	CD	2.1%	2.1%	2.1%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
versus	NN	versus	versus	versu	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
erythema	NN	erythema	erythema	erythema	Y	I-AdverseReaction
(	(	(	(	(	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
versus	NN	versus	versus	versu	N	O
1.7%	CD	1.7%	1.7%	1.7%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
versus	NN	versus	versus	versu	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
(	(	(	(	(	N	O
0%	CD	0%	0%	0%	N	O
versus	NN	versus	versus	versu	N	O
1.4%	CD	1.4%	1.4%	1.4%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
versus	NN	versus	versus	versu	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	I-AdverseReaction
(	(	(	(	(	N	O
0%	CD	0%	0%	0%	N	O
versus	NN	versus	versus	versu	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
versus	NN	versus	versus	versu	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
(	(	(	(	(	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
versus	NN	versus	versus	versu	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
versus	NN	versus	versus	versu	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pruritus	NN	pruritus	pruritus	pruritu	Y	I-AdverseReaction
also	RB	also	also	also	N	O
contributed	VBD	contributed	contributed	contribut	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
frequently	RB	frequently	frequently	frequent	N	O
reported	VBN	reported	reported	report	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
were	VBD	were	were	were	N	O
judged	VBN	judged	judged	judg	N	O
as	IN	as	a	as	N	O
"	JJ	"	"	"	N	O
mild	NN	mild	mild	mild	N	B-Severity
"	NN	"	"	"	N	O
by	IN	by	by	by	N	O
investigators	NNS	investigators	investigator	investig	N	O
in	IN	in	in	in	N	O
both	DT	both	both	both	N	O
groups	NNS	groups	group	group	N	O
(	(	(	(	(	N	O
73%	CD	73%	73%	73%	N	O
for	IN	for	for	for	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
versus	NN	versus	versus	versu	N	O
94%	CD	94%	94%	94%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

More	JJR	more	more	more	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
than	IN	than	than	than	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
:	:	:	:	:	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
an	DT	an	an	an	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
versus	IN	versus	versus	versu	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
experienced	VBD	experienced	experienced	experienc	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
2	CD	2	2	2	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
38%	CD	38%	38%	38%	N	O
versus	IN	versus	versus	versu	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
reaction	NN	reaction	reaction	reaction	N	O
judged	VBN	judged	judged	judg	N	O
by	IN	by	by	by	N	O
investigators	NNS	investigators	investigator	investig	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
"	JJ	"	"	"	N	O
moderate	JJ	moderate	moderate	moder	N	O
"	NN	"	"	"	N	O
or	CC	or	or	or	N	O
"	VB	"	"	"	N	O
severe	JJ	severe	severe	sever	N	O
"	NNP	"	"	"	N	O
(	(	(	(	(	N	O
27%	CD	27%	27%	27%	N	O
versus	IN	versus	versus	versu	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
required	JJ	required	required	requir	N	O
local	JJ	local	local	local	N	O
or	CC	or	or	or	N	O
systemic	JJ	systemic	systemic	system	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
36%	CD	36%	36%	36%	N	O
versus	IN	versus	versus	versu	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
and	CC	and	and	and	N	O
Active	NNP	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBD	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O

The	DT	the	the	the	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
was	VBD	was	wa	wa	N	O
also	RB	also	also	also	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
larger	JJR	larger	larger	larger	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
type	JJ	type	type	type	N	O
2	CD	2	2	2	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
participating	VBG	participating	participating	particip	N	O
in	IN	in	in	in	N	O
7	CD	7	7	7	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
and	CC	and	and	and	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
trials	NNS	trials	trial	trial	N	O
evaluated	VBD	evaluated	evaluated	evalu	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
as	IN	as	a	as	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
as	IN	as	a	as	N	O
add	JJ	add	add	add	Y	O
-	:	-	-	-	N	O
on	IN	on	on	on	N	O
therapy	NN	therapy	therapy	therapi	N	O
to	TO	to	to	to	N	O
oral	JJ	oral	oral	oral	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
agents	NNS	agents	agent	agent	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
as	IN	as	a	as	N	O
add	JJ	add	add	add	Y	O
-	:	-	-	-	N	O
on	IN	on	on	on	N	O
therapy	NN	therapy	therapy	therapi	N	O
to	TO	to	to	to	N	O
basal	VB	basal	basal	basal	N	O
insulin	NN	insulin	insulin	insulin	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
pool	NN	pool	pool	pool	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
116	CD	116	116	116	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
type	JJ	type	type	type	N	O
2	CD	2	2	2	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
75	CD	75	75	75	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
was	VBD	was	wa	wa	N	O
55	CD	55	55	55	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
studies	NNS	studies	study	studi	N	O
was	VBD	was	wa	wa	N	O
75	CD	75	75	75	N	O
years	NNS	years	year	year	N	O
or	CC	or	or	or	N	O
older	JJR	older	older	older	N	O
and	CC	and	and	and	N	O
51%	CD	51%	51%	51%	N	O
of	IN	of	of	of	N	O
participants	NNS	participants	participant	particip	N	O
were	VBD	were	were	were	N	O
male	JJ	male	male	male	N	O
.	.	.	.	.	N	O

Forty	NNP	forty	forty	forti	N	O
-	:	-	-	-	N	O
eight	CD	eight	eight	eight	N	O
percent	NN	percent	percent	percent	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
white	JJ	white	white	white	N	O
,	,	,	,	,	N	O
15%	CD	15%	15%	15%	N	O
African	JJ	african	african	african	N	O
African	JJ	african	african	african	N	O
American	NNP	american	american	american	N	O
,	,	,	,	,	N	O
9%	CD	9%	9%	9%	N	O
Asian	JJ	asian	asian	asian	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
26%	CD	26%	26%	26%	N	O
were	VBD	were	were	were	N	O
Hispanic	NNP	hispanic	hispanic	hispan	N	O
Latino	NNP	latino	latino	latino	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
had	VBD	had	had	had	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
for	IN	for	for	for	N	O
an	DT	an	an	an	N	O
average	NN	average	average	averag	N	O
of	IN	of	of	of	N	O
8	CD	8	8	8	N	O
years	NNS	years	year	year	N	O
and	CC	and	and	and	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
HbA1c	NNP	hba1c	hba1c	hba1c	Y	O
of	IN	of	of	of	N	O
8.2%	CD	8.2%	8.2%	8.2%	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
21%	CD	21%	21%	21%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
reported	VBD	reported	reported	report	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	O
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	O
and	CC	and	and	and	N	O
5%	CD	5%	5%	5%	N	O
reported	VBD	reported	reported	report	N	O
retinopathy	NN	retinopathy	retinopathy	retinopathi	Y	O
.	.	.	.	.	N	O

Baseline	NNP	baseline	baseline	baselin	N	O
estimated	VBD	estimated	estimated	estim	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
was	VBD	was	wa	wa	N	O
normal	JJ	normal	normal	normal	N	O
or	CC	or	or	or	N	O
mildly	RB	mildly	mildly	mildli	N	O
impaired	JJ	impaired	impaired	impair	N	O
(	(	(	(	(	N	O
eGFR	JJ	egfr	egfr	egfr	N	O
60	CD	60	60	60	N	O
mL	NN	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
92%	CD	92%	92%	92%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
and	CC	and	and	and	N	O
moderately	RB	moderately	moderately	moder	N	O
impaired	JJ	impaired	impaired	impair	N	O
(	(	(	(	(	N	O
eGFR	JJ	egfr	egfr	egfr	N	O
30	CD	30	30	30	N	O
to	TO	to	to	to	N	O
60	CD	60	60	60	N	O
mL	NNS	ml	ml	ml	N	O
min	RB	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NNS	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
8%	CD	8%	8%	8%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
and	CC	and	and	and	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
types	NNS	types	type	type	N	O
and	CC	and	and	and	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
excluding	VBG	excluding	excluding	exclud	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
those	DT	those	those	those	N	O
listed	VBN	listed	listed	list	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

Hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
documented	VBN	documented	documented	document	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	B-Severity
hypoglycemic	JJ	hypoglycemic	hypoglycemic	hypoglycem	N	B-AdverseReaction
episode	NN	episode	episode	episod	N	I-AdverseReaction
on	IN	on	on	on	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
severe	JJ	severe	severe	sever	N	B-Severity
hypoglycemic	JJ	hypoglycemic	hypoglycemic	hypoglycem	N	B-AdverseReaction
episode	NN	episode	episode	episod	N	I-AdverseReaction
on	IN	on	on	on	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)]	NN	)]	)]	)]	N	O
is	VBZ	is	is	is	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
when	WRB	when	when	when	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
was	VBD	was	wa	wa	N	O
added	VBN	added	added	ad	N	O
to	TO	to	to	to	N	O
sulfonylurea	VB	sulfonylurea	sulfonylurea	sulfonylurea	N	O
or	CC	or	or	or	N	O
insulin	VB	insulin	insulin	insulin	Y	O
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Incidence	NNP	incidence	incidence	incid	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
Hypoglycemia	NNP	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
in	IN	in	in	in	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Trials	NNP	trials	trial	trial	N	O
of	IN	of	of	of	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
a	DT	a	a	a	N	O

TANZEUM	NN	tanzeum	tanzeum	tanzeum	N	O

Monotherapyb	NNP	monotherapyb	monotherapyb	monotherapyb	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
30	CD	30	30	30	N	O
mg	NNS	mg	mg	mg	N	O
Weekly	JJ	weekly	weekly	weekli	N	O

(	(	(	(	(	N	O
52	CD	52	52	52	N	O
Weeks	NNP	weeks	week	week	N	O
)	)	)	)	)	N	O
N	NNP	n	n	n	N	O
101	CD	101	101	101	N	O
N	NNP	n	n	n	N	O
101	CD	101	101	101	N	O

Documented	VBN	documented	documented	document	N	O
symptomaticc	VBD	symptomaticc	symptomaticc	symptomaticc	N	O
2%	CD	2%	2%	2%	N	O
2%	CD	2%	2%	2%	N	O

Severed	NNP	severed	severed	sever	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

In	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
with	IN	with	with	with	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
Trial	NNP	trial	trial	trial	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O

(	(	(	(	(	N	O
104	CD	104	104	104	N	O
Weeks	NNP	weeks	week	week	N	O
)	)	)	)	)	N	O
e	VBP	e	e	e	N	O
N	$	n	n	n	N	O
101	CD	101	101	101	N	O
N	NNP	n	n	n	N	O
302	CD	302	302	302	N	O

Documented	VBN	documented	documented	document	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
4%	CD	4%	4%	4%	N	O
3%	CD	3%	3%	3%	N	O

Severe	NNP	severe	severe	sever	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

In	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
with	IN	with	with	with	N	O
Pioglitazone	NNP	pioglitazone	pioglitazone	pioglitazon	N	O
-	:	-	-	-	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O

Metformin	NNP	metformin	metformin	metformin	N	O
(	(	(	(	(	N	O
52	CD	52	52	52	N	O
Weeks	NNP	weeks	week	week	N	O
)	)	)	)	)	N	O
N	NNP	n	n	n	N	O
151	CD	151	151	151	N	O
N	NNP	n	n	n	N	O
150	CD	150	150	150	N	O

Documented	VBN	documented	documented	document	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
1%	CD	1%	1%	1%	N	O
3%	CD	3%	3%	3%	N	O

Severe	NNP	severe	severe	sever	N	O
-	:	-	-	-	N	O
1%	CD	1%	1%	1%	N	O

In	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
with	IN	with	with	with	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
and	CC	and	and	and	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O

Sulfonylurea	NNP	sulfonylurea	sulfonylurea	sulfonylurea	N	O
(	(	(	(	(	N	O
52	CD	52	52	52	N	O
Weeks	NNP	weeks	week	week	N	O
)	)	)	)	)	N	O
N	NNP	n	n	n	N	O
115	CD	115	115	115	N	O
N	NNP	n	n	n	N	O
271	CD	271	271	271	N	O

Documented	VBN	documented	documented	document	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
7%	CD	7%	7%	7%	N	O
13%	CD	13%	13%	13%	N	O

Severe	NNP	severe	severe	sever	N	O
-	:	-	-	-	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O

In	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
with	IN	with	with	with	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
Lispro	NNP	lispro	lispro	lispro	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O

Insulin	NNP	insulin	insulin	insulin	Y	O
Glargine	NNP	glargine	glargine	glargin	N	O
(	(	(	(	(	N	O
26	CD	26	26	26	N	O
Weeks	NNP	weeks	week	week	N	O
)	)	)	)	)	N	O
N	NNP	n	n	n	N	O
281	CD	281	281	281	N	O
N	NNP	n	n	n	N	O
285	CD	285	285	285	N	O

Documented	VBN	documented	documented	document	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
30%	CD	30%	30%	30%	N	O
16%	CD	16%	16%	16%	N	O

Severe	RB	severe	severe	sever	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
-	:	-	-	-	N	O

In	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
with	IN	with	with	with	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
Glargine	NNP	glargine	glargine	glargin	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O

Metformin	NNP	metformin	metformin	metformin	N	O
-	:	-	-	-	N	O
Sulfonylurea	NNP	sulfonylurea	sulfonylurea	sulfonylurea	N	O
(	(	(	(	(	N	O
52	CD	52	52	52	N	O
Weeks	NNP	weeks	week	week	N	O
)	)	)	)	)	N	O
N	NNP	n	n	n	N	O
241	CD	241	241	241	N	O
N	NNP	n	n	n	N	O
504	CD	504	504	504	N	O

Documented	VBN	documented	documented	document	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
27%	CD	27%	27%	27%	N	O
17%	CD	17%	17%	17%	N	O

Severe	RB	severe	severe	sever	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O

In	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
with	IN	with	with	with	N	O
OADs	NNP	oads	oads	oad	N	O
in	IN	in	in	in	N	O
Renal	NNP	renal	renal	renal	N	O
Sitagliptin	NNP	sitagliptin	sitagliptin	sitagliptin	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O

Impairment	NNP	impairment	impairment	impair	N	O
(	(	(	(	(	N	O
26	CD	26	26	26	N	O
Weeks	NNP	weeks	week	week	N	O
)	)	)	)	)	N	O
N	NNP	n	n	n	N	O
246	CD	246	246	246	N	O
N	NNP	n	n	n	N	O
249	CD	249	249	249	N	O

Documented	VBN	documented	documented	document	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
6%	CD	6%	6%	6%	N	O
10%	CD	10%	10%	10%	N	O

Severe	RB	severe	severe	sever	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
-	:	-	-	-	N	O

OAD	NNP	oad	oad	oad	N	O
Oral	NNP	oral	oral	oral	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
agents	NNS	agents	agent	agent	N	O
.	.	.	.	.	N	O

a	DT	a	a	a	N	O
Data	NNP	data	data	data	N	O
presented	VBN	presented	presented	present	N	O
are	VBP	are	are	are	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
primary	JJ	primary	primary	primari	N	O
endpoint	NN	endpoint	endpoint	endpoint	N	O
and	CC	and	and	and	N	O
include	VBP	include	include	includ	N	O
only	JJ	only	only	onli	N	O
events	NNS	events	event	event	N	O
occurring	VBG	occurring	occurring	occur	N	O
on	IN	on	on	on	N	O
-	:	-	-	-	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
randomized	JJ	randomized	randomized	random	N	O
medications	NNS	medications	medication	medic	N	O
and	CC	and	and	and	N	O
excludes	VBZ	excludes	excludes	exclud	N	O
events	NNS	events	event	event	N	O
occurring	VBG	occurring	occurring	occur	N	O
after	IN	after	after	after	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
glycemic	JJ	glycemic	glycemic	glycem	N	O
rescue	NN	rescue	rescue	rescu	N	O
medications	NNS	medications	medication	medic	N	O
(	(	(	(	(	N	O
i	NN	i	i	i	N	O
.	.	.	.	.	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
primarily	RB	primarily	primarily	primarili	N	O
metformin	VBZ	metformin	metformin	metformin	N	O
or	CC	or	or	or	N	O
insulin	NN	insulin	insulin	insulin	Y	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

b	NN	b	b	b	N	O
In	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
no	DT	no	no	no	N	B-Negation
documented	JJ	documented	documented	document	N	O
symptomatic	NN	symptomatic	symptomatic	symptomat	N	B-Severity
or	CC	or	or	or	N	O
severe	JJ	severe	severe	sever	N	B-Severity
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
for	IN	for	for	for	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
these	DT	these	these	these	N	O
data	NNS	data	data	data	N	O
are	VBP	are	are	are	N	O
omitted	VBN	omitted	omitted	omit	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
table	NN	table	table	tabl	N	O
.	.	.	.	.	N	O

c	NNS	c	c	c	N	O
Plasma	NNP	plasma	plasma	plasma	N	B-AdverseReaction
glucose	VBP	glucose	glucose	glucos	Y	I-AdverseReaction
concentration	NN	concentration	concentration	concentr	N	I-AdverseReaction
70	CD	70	70	70	N	I-AdverseReaction
mg	NN	mg	mg	mg	N	I-AdverseReaction
dL	NN	dl	dl	dl	N	I-AdverseReaction
and	CC	and	and	and	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
hypoglycemic	JJ	hypoglycemic	hypoglycemic	hypoglycem	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
.	.	.	.	.	N	O

d	JJ	d	d	d	N	O
Event	NNP	event	event	event	N	O
requiring	VBG	requiring	requiring	requir	N	O
another	DT	another	another	anoth	N	O
person	NN	person	person	person	N	O
to	TO	to	to	to	N	O
administer	VB	administer	administer	administ	N	O
a	DT	a	a	a	N	O
resuscitative	JJ	resuscitative	resuscitative	resuscit	N	O
action	NN	action	action	action	N	O
.	.	.	.	.	N	O

e	NN	e	e	e	N	O
Rate	NNP	rate	rate	rate	N	O
of	IN	of	of	of	N	O
documented	VBN	documented	documented	document	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	B-Severity
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
for	IN	for	for	for	N	O
active	JJ	active	active	activ	N	O
controls	NNS	controls	control	control	N	O
18%	CD	18%	18%	18%	N	O
(	(	(	(	(	N	O
glimepiride	NN	glimepiride	glimepiride	glimepirid	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
sitagliptin	NN	sitagliptin	sitagliptin	sitagliptin	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	O

In	IN	in	in	in	N	O

the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
7	CD	7	7	7	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
and	CC	and	and	and	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
of	IN	of	of	of	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
(	(	(	(	(	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
)	)	)	)	)	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
all	DT	all	all	all	N	O
-	:	-	-	-	N	O
comparators	NNS	comparators	comparators	compar	N	O
group	NN	group	group	group	N	O
(	(	(	(	(	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

More	RBR	more	more	more	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
group	NN	group	group	group	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
were	VBD	were	were	were	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
(	(	(	(	(	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
for	IN	for	for	for	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
versus	NN	versus	versus	versu	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
for	IN	for	for	for	N	O
all	DT	all	all	all	N	O
comparators	NNS	comparators	comparators	compar	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Atrial	JJ	atrial	atrial	atrial	N	O
Fibrillation	NNP	fibrillation	fibrillation	fibril	Y	O
Flutte	NNP	flutte	flutte	flutt	N	O
r	NN	r	r	r	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
7	CD	7	7	7	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
and	CC	and	and	and	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
atrial	JJ	atrial	atrial	atrial	N	B-AdverseReaction
fibrillation	NN	fibrillation	fibrillation	fibril	Y	I-AdverseReaction
(	(	(	(	(	N	O
1.0%	CD	1.0%	1.0%	1.0%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
atrial	JJ	atrial	atrial	atrial	N	B-AdverseReaction
flutter	NN	flutter	flutter	flutter	N	I-AdverseReaction
(	(	(	(	(	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
for	IN	for	for	for	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
than	IN	than	than	than	N	O
for	IN	for	for	for	N	O
all	DT	all	all	all	N	O
comparators	NNS	comparators	comparators	compar	N	O
(	(	(	(	(	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
and	CC	and	and	and	N	O
0%	CD	0%	0%	0%	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
both	DT	both	both	both	N	O
groups	NNS	groups	group	group	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
generally	RB	generally	generally	gener	N	O
male	JJ	male	male	male	N	O
,	,	,	,	,	N	O
older	JJR	older	older	older	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
had	VBD	had	had	had	N	O
underlying	JJ	underlying	underlying	underli	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
or	CC	or	or	or	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
disease	NN	disease	disease	diseas	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
arrhythmia	NN	arrhythmia	arrhythmia	arrhythmia	Y	O
,	,	,	,	,	N	O
palpitations	NNS	palpitations	palpitation	palpit	Y	O
,	,	,	,	,	N	O
congestive	JJ	congestive	congestive	congest	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
,	,	,	,	,	N	O
cardiomyopathy	NN	cardiomyopathy	cardiomyopathy	cardiomyopathi	Y	O
,	,	,	,	,	N	O
etc	FW	etc	etc	etc	N	O
.	.	.	.	.	N	O

)	)	)	)	)	N	O
.	.	.	.	.	N	O

Appendicitis	NN	appendicitis	appendicitis	append	Y	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
and	CC	and	and	and	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
events	NNS	events	event	event	N	O
of	IN	of	of	of	N	O
appendicitis	NN	appendicitis	appendicitis	append	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
0%	CD	0%	0%	0%	N	O
among	IN	among	among	among	N	O
all	DT	all	all	all	N	O
comparators	NNS	comparators	comparators	compar	N	O
.	.	.	.	.	N	O

Immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
7	CD	7	7	7	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
and	CC	and	and	and	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
116	CD	116	116	116	N	O
(	(	(	(	(	N	O
5.5%	CD	5.5%	5.5%	5.5%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
098	CD	098	098	098	N	O
patients	NNS	patients	patient	patient	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
albiglutide	NN	albiglutide	albiglutide	albiglutid	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
at	IN	at	at	at	N	O
any	DT	any	any	ani	N	O
time	NN	time	time	time	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

None	NN	none	none	none	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
were	VBD	were	were	were	N	O
shown	VBN	shown	shown	shown	N	O
to	TO	to	to	to	N	O
neutralize	VB	neutralize	neutralize	neutral	N	O
the	DT	the	the	the	N	O
activity	NN	activity	activity	activ	N	O
of	IN	of	of	of	N	O
albiglutide	NN	albiglutide	albiglutide	albiglutid	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
in	IN	in	in	in	N	O
vitro	NN	vitro	vitro	vitro	N	O
bioassay	NN	bioassay	bioassay	bioassay	N	O
.	.	.	.	.	N	O

Presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
correlate	VB	correlate	correlate	correl	N	O
with	IN	with	with	with	N	O
reduced	JJ	reduced	reduced	reduc	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
as	IN	as	a	as	N	O
measured	VBN	measured	measured	measur	N	O
by	IN	by	by	by	N	O
HbA1c	NNP	hba1c	hba1c	hba1c	Y	O
and	CC	and	and	and	N	O
fasting	VBG	fasting	fasting	fast	Y	O
plasma	NN	plasma	plasma	plasma	N	O
glucose	NN	glucose	glucose	glucos	Y	O
or	CC	or	or	or	N	O
specific	JJ	specific	specific	specif	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

Consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
high	JJ	high	high	high	N	O
homology	NN	homology	homology	homolog	N	O
of	IN	of	of	of	N	O
albiglutide	NN	albiglutide	albiglutide	albiglutid	N	O
with	IN	with	with	with	N	O
human	JJ	human	human	human	N	O
GLP	NNP	glp	glp	glp	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
approximately	RB	approximately	approximately	approxim	N	O
79%	CD	79%	79%	79%	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
albiglutide	NN	albiglutide	albiglutide	albiglutid	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
also	RB	also	also	also	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
GLP	NNP	glp	glp	glp	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
;	:	;	;	;	N	O
none	NN	none	none	none	N	O
were	VBD	were	were	were	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
minority	NN	minority	minority	minor	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
approximately	RB	approximately	approximately	approxim	N	O
17%	CD	17%	17%	17%	N	O
)	)	)	)	)	N	O
who	WP	who	who	who	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
albiglutide	NN	albiglutide	albiglutide	albiglutid	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
also	RB	also	also	also	N	O
transiently	RB	transiently	transiently	transient	N	O
tested	VBN	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
human	JJ	human	human	human	N	O
albumin	NN	albumin	albumin	albumin	Y	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
detection	NN	detection	detection	detect	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
formation	NN	formation	formation	format	N	O
is	VBZ	is	is	is	N	O
highly	RB	highly	highly	highli	N	O
dependent	JJ	dependent	dependent	depend	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
and	CC	and	and	and	N	O
specificity	NN	specificity	specificity	specif	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
assay	NN	assay	assay	assay	N	O
.	.	.	.	.	N	O

Additionally	RB	additionally	additionally	addit	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
observed	JJ	observed	observed	observ	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibody	NN	antibody	antibody	antibodi	N	O
)	)	)	)	)	N	O
positivity	NN	positivity	positivity	posit	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
assay	NN	assay	assay	assay	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
influenced	VBN	influenced	influenced	influenc	N	O
by	IN	by	by	by	N	O
several	JJ	several	several	sever	N	O
factors	NNS	factors	factor	factor	N	O
including	VBG	including	including	includ	N	O
assay	JJ	assay	assay	assay	N	O
methodology	NN	methodology	methodology	methodolog	N	O
,	,	,	,	,	N	O
sample	NN	sample	sample	sampl	N	O
handling	NN	handling	handling	handl	N	O
,	,	,	,	,	N	O
timing	NN	timing	timing	time	N	O
of	IN	of	of	of	N	O
sample	JJ	sample	sample	sampl	N	O
collection	NN	collection	collection	collect	N	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
underlying	JJ	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
these	DT	these	these	these	N	O
reasons	NNS	reasons	reason	reason	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
albiglutide	VB	albiglutide	albiglutide	albiglutid	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
of	IN	of	of	of	N	O
other	JJ	other	other	other	N	O
products	NNS	products	product	product	N	O
.	.	.	.	.	N	O

Liver	NNP	liver	liver	liver	N	O
Enzyme	NNP	enzyme	enzyme	enzym	N	O
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
and	CC	and	and	and	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
similar	JJ	similar	similar	similar	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
experienced	VBN	experienced	experienced	experienc	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
event	NN	event	event	event	N	O
of	IN	of	of	of	N	O
alanine	JJ	alanine	alanine	alanin	N	B-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
)	)	)	)	)	N	O
increase	NN	increase	increase	increas	N	I-AdverseReaction
of	IN	of	of	of	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
fold	NN	fold	fold	fold	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
above	IN	above	above	abov	N	O
the	DT	the	the	the	N	O
upper	JJ	upper	upper	upper	N	O
limit	NN	limit	limit	limit	N	O
of	IN	of	of	of	N	O
normal	JJ	normal	normal	normal	N	O
(	(	(	(	(	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
and	CC	and	and	and	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
for	IN	for	for	for	N	O
all	DT	all	all	all	N	O
comparators	NNS	comparators	comparators	compar	N	O
versus	VBP	versus	versus	versu	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Three	CD	three	three	three	N	O
subjects	NNS	subjects	subject	subject	N	O
on	IN	on	on	on	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
subject	NN	subject	subject	subject	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
all	DT	all	all	all	N	O
-	:	-	-	-	N	O
comparator	NN	comparator	comparator	compar	N	O
group	NN	group	group	group	N	O
experienced	VBD	experienced	experienced	experienc	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
event	NN	event	event	event	N	O
of	IN	of	of	of	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
increase	NN	increase	increase	increas	N	I-AdverseReaction
of	IN	of	of	of	N	O
10	CD	10	10	10	N	O
-	:	-	-	-	N	O
fold	NN	fold	fold	fold	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
above	IN	above	above	abov	N	O
the	DT	the	the	the	N	O
upper	JJ	upper	upper	upper	N	O
limit	NN	limit	limit	limit	N	O
of	IN	of	of	of	N	O
normal	JJ	normal	normal	normal	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
one	CD	one	one	one	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
3	CD	3	3	3	N	O
cases	NNS	cases	case	case	N	O
an	DT	an	an	an	N	O
alternate	NN	alternate	alternate	altern	N	B-Negation
etiology	NN	etiology	etiology	etiolog	N	I-Negation
was	VBD	was	wa	wa	N	O
identified	VBN	identified	identified	identifi	N	O
to	TO	to	to	to	N	O
explain	VB	explain	explain	explain	N	O
the	DT	the	the	the	N	O
rise	NN	rise	rise	rise	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
liver	NN	liver	liver	liver	N	I-AdverseReaction
enzyme	NN	enzyme	enzyme	enzym	N	I-AdverseReaction
(	(	(	(	(	N	O
acute	JJ	acute	acute	acut	N	O
viral	JJ	viral	viral	viral	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
one	CD	one	one	one	N	O
case	NN	case	case	case	N	O
,	,	,	,	,	N	O
insufficient	JJ	insufficient	insufficient	insuffici	N	O
information	NN	information	information	inform	N	O
was	VBD	was	wa	wa	N	O
obtained	VBN	obtained	obtained	obtain	N	O
to	TO	to	to	to	N	O
establish	VB	establish	establish	establish	N	O
or	CC	or	or	or	N	O
refute	VB	refute	refute	refut	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
causality	NN	causality	causality	causal	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
third	JJ	third	third	third	N	O
case	NN	case	case	case	N	O
,	,	,	,	,	N	O
elevation	NN	elevation	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
(	(	(	(	(	N	O
10	CD	10	10	10	N	B-Severity
times	NNS	times	time	time	N	I-Severity
the	DT	the	the	the	N	I-Severity
upper	JJ	upper	upper	upper	N	I-Severity
limit	NN	limit	limit	limit	N	I-Severity
of	IN	of	of	of	N	I-Severity
normal	JJ	normal	normal	normal	N	I-Severity
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
accompanied	VBN	accompanied	accompanied	accompani	N	O
by	IN	by	by	by	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
total	JJ	total	total	total	N	I-AdverseReaction
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
(	(	(	(	(	N	O
4	CD	4	4	4	N	B-Severity
times	NNS	times	time	time	N	I-Severity
the	DT	the	the	the	N	I-Severity
upper	JJ	upper	upper	upper	N	I-Severity
limit	NN	limit	limit	limit	N	I-Severity
of	IN	of	of	of	N	I-Severity
normal	JJ	normal	normal	normal	N	I-Severity
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
occurred	VBD	occurred	occurred	occur	N	O
8	CD	8	8	8	N	O
days	NNS	days	day	day	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
etiology	NN	etiology	etiology	etiolog	N	O
of	IN	of	of	of	N	O
hepatocellular	JJ	hepatocellular	hepatocellular	hepatocellular	N	B-AdverseReaction
injury	NN	injury	injury	injuri	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
possibly	RB	possibly	possibly	possibl	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
but	CC	but	but	but	N	O
direct	JJ	direct	direct	direct	N	O
attribution	NN	attribution	attribution	attribut	N	O
to	TO	to	to	to	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
was	VBD	was	wa	wa	N	O
confounded	VBN	confounded	confounded	confound	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
gallstone	NN	gallstone	gallstone	gallston	N	O
disease	NN	disease	disease	diseas	N	O
diagnosed	VBD	diagnosed	diagnosed	diagnos	N	O
on	IN	on	on	on	N	O
ultrasound	IN	ultrasound	ultrasound	ultrasound	N	O
3	CD	3	3	3	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
event	NN	event	event	event	N	O
.	.	.	.	.	N	O

Gamma	NNP	gamma	gamma	gamma	N	O
Glutamyltransferase	NNP	glutamyltransferase	glutamyltransferase	glutamyltransferas	N	O
(	(	(	(	(	N	O
GGT	NNP	ggt	ggt	ggt	Y	O
)	)	)	)	)	N	O
Increase	NN	increase	increase	increas	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
event	NN	event	event	event	N	O
of	IN	of	of	of	N	O
increased	VBN	increased	increased	increas	N	B-AdverseReaction
GGT	NNP	ggt	ggt	ggt	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
group	NN	group	group	group	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
(	(	(	(	(	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
and	CC	and	and	and	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
versus	NN	versus	versus	versu	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Heart	NNP	heart	heart	heart	N	O
Rate	NNP	rate	rate	rate	N	O
Increase	NNP	increase	increase	increas	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
mean	JJ	mean	mean	mean	N	B-AdverseReaction
heart	NN	heart	heart	heart	N	I-AdverseReaction
rate	NN	rate	rate	rate	N	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
was	VBD	was	wa	wa	N	O
higher	JJR	higher	higher	higher	N	I-AdverseReaction
by	IN	by	by	by	N	I-AdverseReaction
an	DT	an	an	an	N	I-AdverseReaction
average	NN	average	average	averag	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
1	CD	1	1	1	N	I-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
2	CD	2	2	2	N	I-AdverseReaction
bpm	NNS	bpm	bpm	bpm	N	I-AdverseReaction
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
mean	JJ	mean	mean	mean	N	O
heart	NN	heart	heart	heart	N	O
rate	NN	rate	rate	rate	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
across	IN	across	across	across	N	O
study	NN	study	study	studi	N	O
visits	NNS	visits	visit	visit	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
clinical	JJ	clinical	clinical	clinic	N	O
effects	NNS	effects	effect	effect	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
increase	NN	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
heart	NN	heart	heart	heart	N	I-AdverseReaction
rate	NN	rate	rate	rate	N	I-AdverseReaction
have	VBP	have	have	have	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
established	VBN	established	established	establish	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
RISK	NN	risk	risk	risk	N	B-Factor
OF	IN	of	of	of	N	O
THYROID	NNP	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
CELL	NN	cell	cell	cell	N	I-AdverseReaction
TUMORS	NNP	tumors	tumor	tumor	N	I-AdverseReaction
\n\n	VBD	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
RISK	NN	risk	risk	risk	N	B-Factor
OF	IN	of	of	of	N	O
THYROID	NNP	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
CELL	NN	cell	cell	cell	N	I-AdverseReaction
TUMORS	NNP	tumors	tumor	tumor	N	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
Carcinogenicity	NNP	carcinogenicity	carcinogenicity	carcinogen	Y	O
of	IN	of	of	of	N	O
albiglutide	NN	albiglutide	albiglutide	albiglutid	N	O
could	MD	could	could	could	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
assessed	VBN	assessed	assessed	assess	N	O
in	IN	in	in	in	N	O
rodents	NNS	rodents	rodent	rodent	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
other	JJ	other	other	other	N	O
glucagon	NN	glucagon	glucagon	glucagon	Y	B-DrugClass
-	:	-	-	-	N	I-DrugClass
like	IN	like	like	like	N	I-DrugClass
peptide	IN	peptide	peptide	peptid	N	I-DrugClass
-	:	-	-	-	N	I-DrugClass
1	CD	1	1	1	N	I-DrugClass
(	(	(	(	(	N	I-DrugClass
GLP	NNP	glp	glp	glp	N	I-DrugClass
-	:	-	-	-	N	I-DrugClass
1	CD	1	1	1	N	I-DrugClass
)	)	)	)	)	N	I-DrugClass
receptor	NN	receptor	receptor	receptor	N	I-DrugClass
agonists	NNS	agonists	agonist	agonist	N	I-DrugClass
have	VBP	have	have	have	N	O
caused	VBN	caused	caused	caus	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
tumors	NNS	tumors	tumor	tumor	N	I-AdverseReaction
in	IN	in	in	in	N	O
rodents	NNS	rodents	rodent	rodent	N	B-Animal
at	IN	at	at	at	N	O
clinically	RB	clinically	clinically	clinic	N	O
relevant	JJ	relevant	relevant	relev	N	O
exposures	NNS	exposures	exposure	exposur	N	O
.	.	.	.	.	N	O

Human	JJ	human	human	human	N	O
relevance	NN	relevance	relevance	relev	N	O
of	IN	of	of	of	N	O
GLP	NNP	glp	glp	glp	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
1	CD	1	1	1	N	I-DrugClass
receptor	NN	receptor	receptor	receptor	N	I-DrugClass
agonist	NN	agonist	agonist	agonist	N	I-DrugClass
induced	VBD	induced	induced	induc	N	O
C	NNP	c	c	c	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
tumors	NNS	tumors	tumor	tumor	N	I-AdverseReaction
in	IN	in	in	in	N	O
rodents	NNS	rodents	rodent	rodent	N	B-Animal
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
determined	VBN	determined	determined	determin	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	B-Factor
whether	IN	whether	whether	whether	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
causes	VBZ	causes	cause	caus	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
tumors	NNS	tumors	tumor	tumor	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
medullary	JJ	medullary	medullary	medullari	N	B-AdverseReaction
thyroid	NN	thyroid	thyroid	thyroid	N	I-AdverseReaction
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
(	(	(	(	(	N	O
MTC	NNP	mtc	mtc	mtc	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
humans	NNS	humans	human	human	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Nonclinical	NNP	nonclinical	nonclinical	nonclin	N	O
Toxicology	NNP	toxicology	toxicology	toxicolog	N	O
(	(	(	(	(	N	O
13.1	CD	13.1	13.1	13.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
is	VBZ	is	is	is	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
personal	JJ	personal	personal	person	N	O
or	CC	or	or	or	N	O
family	NN	family	family	famili	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
MTC	NNP	mtc	mtc	mtc	N	O
or	CC	or	or	or	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Multiple	NNP	multiple	multiple	multipl	N	O
Endocrine	NNP	endocrine	endocrine	endocrin	N	O
Neoplasia	NNP	neoplasia	neoplasia	neoplasia	N	O
syndrome	VBD	syndrome	syndrome	syndrom	N	O
type	JJ	type	type	type	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
MEN	NNP	men	men	men	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Counsel	NNP	counsel	counsel	counsel	N	O
patients	NNS	patients	patient	patient	N	O
regarding	VBG	regarding	regarding	regard	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
MTC	NNP	mtc	mtc	mtc	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
and	CC	and	and	and	N	O
inform	VB	inform	inform	inform	N	O
them	PRP	them	them	them	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
tumors	NNS	tumors	tumor	tumor	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
mass	NN	mass	mass	mass	Y	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
neck	NN	neck	neck	neck	N	O
,	,	,	,	,	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	O
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	O
,	,	,	,	,	N	O
persistent	JJ	persistent	persistent	persist	N	O
hoarseness	NN	hoarseness	hoarseness	hoars	Y	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Routine	JJ	routine	routine	routin	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
serum	JJ	serum	serum	serum	N	O
calcitonin	NN	calcitonin	calcitonin	calcitonin	Y	O
or	CC	or	or	or	N	O
using	VBG	using	using	use	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
ultrasound	JJ	ultrasound	ultrasound	ultrasound	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
is	VBZ	is	is	is	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
value	NN	value	value	valu	N	O
for	IN	for	for	for	N	O
early	JJ	early	early	earli	N	O
detection	NN	detection	detection	detect	N	O
of	IN	of	of	of	N	O
MTC	NNP	mtc	mtc	mtc	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4.1	CD	4.1	4.1	4.1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
RISK	NN	risk	risk	risk	N	B-Factor
OF	IN	of	of	of	N	O
THYROID	NNP	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
CELL	NN	cell	cell	cell	N	I-AdverseReaction
TUMORS	NNP	tumors	tumor	tumor	N	I-AdverseReaction
\n	NNP	\n	\n	\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

Carcinogenicity	NN	carcinogenicity	carcinogenicity	carcinogen	Y	O
of	IN	of	of	of	N	O
albiglutide	NN	albiglutide	albiglutide	albiglutid	N	O
could	MD	could	could	could	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
assessed	VBN	assessed	assessed	assess	N	O
in	IN	in	in	in	N	O
rodents	NNS	rodents	rodent	rodent	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
other	JJ	other	other	other	N	O
glucagon	NN	glucagon	glucagon	glucagon	Y	B-DrugClass
-	:	-	-	-	N	I-DrugClass
like	IN	like	like	like	N	I-DrugClass
peptide	IN	peptide	peptide	peptid	N	I-DrugClass
-	:	-	-	-	N	I-DrugClass
1	CD	1	1	1	N	I-DrugClass
(	(	(	(	(	N	I-DrugClass
GLP	NNP	glp	glp	glp	N	I-DrugClass
-	:	-	-	-	N	I-DrugClass
1	CD	1	1	1	N	I-DrugClass
)	)	)	)	)	N	I-DrugClass
receptor	NN	receptor	receptor	receptor	N	I-DrugClass
agonists	NNS	agonists	agonist	agonist	N	I-DrugClass
have	VBP	have	have	have	N	O
caused	VBN	caused	caused	caus	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
tumors	NNS	tumors	tumor	tumor	N	I-AdverseReaction
in	IN	in	in	in	N	O
rodents	NNS	rodents	rodent	rodent	N	B-Animal
at	IN	at	at	at	N	O
clinically	RB	clinically	clinically	clinic	N	O
relevant	JJ	relevant	relevant	relev	N	O
exposures	NNS	exposures	exposure	exposur	N	O
.	.	.	.	.	N	O

Human	JJ	human	human	human	N	O
relevance	NN	relevance	relevance	relev	N	O
of	IN	of	of	of	N	O
GLP	NNP	glp	glp	glp	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
1	CD	1	1	1	N	I-DrugClass
receptor	NN	receptor	receptor	receptor	N	I-DrugClass
agonist	NN	agonist	agonist	agonist	N	I-DrugClass
induced	VBD	induced	induced	induc	N	O
C	NNP	c	c	c	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
tumors	NNS	tumors	tumor	tumor	N	I-AdverseReaction
in	IN	in	in	in	N	O
rodents	NNS	rodents	rodent	rodent	N	B-Animal
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
determined	VBN	determined	determined	determin	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	B-Factor
whether	IN	whether	whether	whether	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
causes	VBZ	causes	cause	caus	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
tumors	NNS	tumors	tumor	tumor	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
medullary	JJ	medullary	medullary	medullari	N	B-AdverseReaction
thyroid	NN	thyroid	thyroid	thyroid	N	I-AdverseReaction
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
(	(	(	(	(	N	O
MTC	NNP	mtc	mtc	mtc	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
humans	NNS	humans	human	human	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
13.1	CD	13.1	13.1	13.1	N	O
)	)	)	)	)	N	O
\n	NN	\n	\n	\n	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
is	VBZ	is	is	is	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
personal	JJ	personal	personal	person	N	O
or	CC	or	or	or	N	O
family	NN	family	family	famili	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
MTC	NNP	mtc	mtc	mtc	N	O
or	CC	or	or	or	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Multiple	NNP	multiple	multiple	multipl	N	O
Endocrine	NNP	endocrine	endocrine	endocrin	N	O
Neoplasia	NNP	neoplasia	neoplasia	neoplasia	N	O
syndrome	VBD	syndrome	syndrome	syndrom	N	O
type	JJ	type	type	type	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
MEN	NNP	men	men	men	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Counsel	NNP	counsel	counsel	counsel	N	O
patients	NNS	patients	patient	patient	N	O
regarding	VBG	regarding	regarding	regard	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
MTC	NNP	mtc	mtc	mtc	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
tumors	NNS	tumors	tumor	tumor	N	O
(	(	(	(	(	N	O
4.1	CD	4.1	4.1	4.1	N	O
,	,	,	,	,	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
\n	$	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Thyroid	NNP	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
Tumors	NNS	tumors	tumor	tumor	N	I-AdverseReaction
:	:	:	:	:	N	O
See	VB	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
:	:	:	:	:	N	O
Discontinue	NNP	discontinue	discontinue	discontinu	N	O
promptly	RB	promptly	promptly	promptli	N	O
if	IN	if	if	if	N	O
suspected	VBN	suspected	suspected	suspect	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
restart	VB	restart	restart	restart	N	O
if	IN	if	if	if	N	O
confirmed	VBN	confirmed	confirmed	confirm	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
other	JJ	other	other	other	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
therapies	NNS	therapies	therapy	therapi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
:	:	:	:	:	N	O
Can	MD	can	can	can	N	O
occur	VB	occur	occur	occur	N	O
when	WRB	when	when	when	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
insulin	NN	insulin	insulin	insulin	Y	O
secretagogues	NNS	secretagogues	secretagogues	secretagogu	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
sulfonylureas	JJ	sulfonylureas	sulfonylurea	sulfonylurea	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
insulin	NN	insulin	insulin	insulin	Y	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
lowering	VBG	lowering	lowering	lower	N	O
sulfonylurea	NN	sulfonylurea	sulfonylurea	sulfonylurea	N	O
or	CC	or	or	or	N	O
insulin	NN	insulin	insulin	insulin	Y	O
dosage	NN	dosage	dosage	dosag	N	O
when	WRB	when	when	when	N	O
starting	VBG	starting	starting	start	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
:	:	:	:	:	N	O
Discontinue	NNP	discontinue	discontinue	discontinu	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
if	IN	if	if	if	N	O
suspected	VBN	suspected	suspected	suspect	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
promptly	RB	promptly	promptly	promptli	N	O
per	IN	per	per	per	N	O
standard	NN	standard	standard	standard	N	O
of	IN	of	of	of	N	O
care	NN	care	care	care	N	O
until	IN	until	until	until	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
resolve	VBP	resolve	resolve	resolv	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
Impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
reporting	NN	reporting	reporting	report	N	O
severe	JJ	severe	severe	sever	N	O
adverse	JJ	adverse	adverse	advers	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
Outcomes	NNS	outcomes	outcome	outcom	N	O
:	:	:	:	:	N	O
There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
no	DT	no	no	no	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
establishing	VBG	establishing	establishing	establish	N	O
conclusive	JJ	conclusive	conclusive	conclus	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
risk	NN	risk	risk	risk	N	O
reduction	NN	reduction	reduction	reduct	N	O
with	IN	with	with	with	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
drug	NN	drug	drug	drug	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
Thyroid	NNP	thyroid	thyroid	thyroid	N	O
C	NNP	c	c	c	N	O
-	:	-	-	-	N	O
cell	NN	cell	cell	cell	N	O
Tumors	NNS	tumors	tumor	tumor	N	O

Carcinogenicity	NN	carcinogenicity	carcinogenicity	carcinogen	Y	O
of	IN	of	of	of	N	O
albiglutide	NN	albiglutide	albiglutide	albiglutid	N	O
could	MD	could	could	could	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
assessed	VBN	assessed	assessed	assess	N	O
in	IN	in	in	in	N	O
rodents	NNS	rodents	rodent	rodent	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
rapid	JJ	rapid	rapid	rapid	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
drug	NN	drug	drug	drug	N	O
-	:	-	-	-	N	O
clearing	NN	clearing	clearing	clear	N	O
,	,	,	,	,	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
drug	NN	drug	drug	drug	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Nonclinical	JJ	nonclinical	nonclinical	nonclin	N	O
Toxicology	NNP	toxicology	toxicology	toxicolog	N	O
(	(	(	(	(	N	O
13.1	CD	13.1	13.1	13.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
GLP	NNP	glp	glp	glp	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
1	CD	1	1	1	N	I-DrugClass
receptor	NN	receptor	receptor	receptor	N	I-DrugClass
agonists	NNS	agonists	agonist	agonist	N	I-DrugClass
have	VBP	have	have	have	N	O
caused	VBN	caused	caused	caus	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
and	CC	and	and	and	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
duration	NN	duration	duration	durat	N	O
-	:	-	-	-	N	O
dependent	JJ	dependent	dependent	depend	N	O
thyroid	NN	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
tumors	NNS	tumors	tumor	tumor	N	I-AdverseReaction
(	(	(	(	(	N	O
adenomas	NN	adenomas	adenoma	adenoma	N	I-AdverseReaction
or	CC	or	or	or	N	O
carcinomas	NN	carcinomas	carcinoma	carcinoma	N	I-AdverseReaction
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
rodents	NNS	rodents	rodent	rodent	N	B-Animal
.	.	.	.	.	N	O

Human	JJ	human	human	human	N	O
relevance	NN	relevance	relevance	relev	N	O
of	IN	of	of	of	N	O
GLP	NNP	glp	glp	glp	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
1	CD	1	1	1	N	I-DrugClass
receptor	NN	receptor	receptor	receptor	N	I-DrugClass
agonist	NN	agonist	agonist	agonist	N	I-DrugClass
induced	VBD	induced	induced	induc	N	O
C	NNP	c	c	c	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
tumors	NNS	tumors	tumor	tumor	N	I-AdverseReaction
in	IN	in	in	in	N	O
rodents	NNS	rodents	rodent	rodent	N	B-Animal
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
determined	VBN	determined	determined	determin	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	B-Factor
whether	IN	whether	whether	whether	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
causes	VBZ	causes	cause	caus	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
tumors	NNS	tumors	tumor	tumor	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
MTC	NNP	mtc	mtc	mtc	N	B-AdverseReaction
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
humans	NNS	humans	human	human	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
,	,	,	,	,	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4.1	CD	4.1	4.1	4.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
8	CD	8	8	8	N	O
Phase	NNP	phase	phase	phase	N	O
III	NNP	iii	iii	iii	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)]	NN	)]	)]	)]	N	O
,	,	,	,	,	N	O
MTC	NNP	mtc	mtc	mtc	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
diagnosed	VBN	diagnosed	diagnosed	diagnos	N	O
in	IN	in	in	in	N	O
1	CD	1	1	1	N	O
patient	NN	patient	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
patient	NN	patient	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Both	DT	both	both	both	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
markedly	RB	markedly	markedly	markedli	N	O
elevated	VBN	elevated	elevated	elev	N	O
serum	NN	serum	serum	serum	N	O
calcitonin	NN	calcitonin	calcitonin	calcitonin	Y	O
levels	NNS	levels	level	level	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
.	.	.	.	.	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
MTC	NNP	mtc	mtc	mtc	N	B-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
liraglutide	NN	liraglutide	liraglutide	liraglutid	N	B-DrugClass
,	,	,	,	,	N	O
another	DT	another	another	anoth	N	O
GLP	NNP	glp	glp	glp	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
receptor	NN	receptor	receptor	receptor	N	O
agonist	NN	agonist	agonist	agonist	N	O
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
postmarketing	JJ	postmarketing	postmarketing	postmarket	N	O
period	NN	period	period	period	N	O
;	:	;	;	;	N	O
the	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
reports	NNS	reports	report	report	N	O
are	VBP	are	are	are	N	O
insufficient	JJ	insufficient	insufficient	insuffici	N	O
to	TO	to	to	to	N	O
establish	VB	establish	establish	establish	N	O
or	CC	or	or	or	N	O
exclude	VB	exclude	exclude	exclud	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
between	IN	between	between	between	N	O
MTC	NNP	mtc	mtc	mtc	N	B-AdverseReaction
and	CC	and	and	and	N	O
GLP	NNP	glp	glp	glp	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
1	CD	1	1	1	N	I-DrugClass
receptor	NN	receptor	receptor	receptor	N	I-DrugClass
agonist	NN	agonist	agonist	agonist	N	I-DrugClass
use	NN	use	use	use	N	O
in	IN	in	in	in	N	O
humans	NNS	humans	human	human	N	O
.	.	.	.	.	N	O

TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
is	VBZ	is	is	is	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
personal	JJ	personal	personal	person	N	O
or	CC	or	or	or	N	O
family	NN	family	family	famili	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
MTC	NNP	mtc	mtc	mtc	N	O
or	CC	or	or	or	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
MEN	NNP	men	men	men	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Counsel	NNP	counsel	counsel	counsel	N	O
patients	NNS	patients	patient	patient	N	O
regarding	VBG	regarding	regarding	regard	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
MTC	NNP	mtc	mtc	mtc	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
and	CC	and	and	and	N	O
inform	VB	inform	inform	inform	N	O
them	PRP	them	them	them	N	O
of	IN	of	of	of	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
tumors	NNS	tumors	tumor	tumor	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
mass	NN	mass	mass	mass	Y	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
neck	NN	neck	neck	neck	N	O
,	,	,	,	,	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	O
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
persistent	JJ	persistent	persistent	persist	N	O
hoarseness	NN	hoarseness	hoarseness	hoars	Y	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Routine	JJ	routine	routine	routin	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
serum	JJ	serum	serum	serum	N	O
calcitonin	NN	calcitonin	calcitonin	calcitonin	Y	O
or	CC	or	or	or	N	O
using	VBG	using	using	use	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
ultrasound	NN	ultrasound	ultrasound	ultrasound	N	O
is	VBZ	is	is	is	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
value	NN	value	value	valu	N	O
for	IN	for	for	for	N	O
early	JJ	early	early	earli	N	O
detection	NN	detection	detection	detect	N	O
of	IN	of	of	of	N	O
MTC	NNP	mtc	mtc	mtc	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
.	.	.	.	.	N	O

Such	JJ	such	such	such	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
unnecessary	JJ	unnecessary	unnecessary	unnecessari	N	O
procedures	NNS	procedures	procedure	procedur	N	O
,	,	,	,	,	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
low	JJ	low	low	low	N	O
specificity	NN	specificity	specificity	specif	N	O
of	IN	of	of	of	N	O
serum	NN	serum	serum	serum	N	O
calcitonin	NN	calcitonin	calcitonin	calcitonin	Y	O
testing	VBG	testing	testing	test	N	O
for	IN	for	for	for	N	O
MTC	NNP	mtc	mtc	mtc	N	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
high	JJ	high	high	high	N	O
background	NN	background	background	background	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

Significantly	RB	significantly	significantly	significantli	N	O
elevated	VBN	elevated	elevated	elev	N	O
serum	JJ	serum	serum	serum	N	O
calcitonin	NN	calcitonin	calcitonin	calcitonin	Y	O
may	MD	may	may	may	N	O
indicate	VB	indicate	indicate	indic	N	O
MTC	NNP	mtc	mtc	mtc	N	O
and	CC	and	and	and	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
MTC	NNP	mtc	mtc	mtc	N	O
usually	RB	usually	usually	usual	N	O
have	VBP	have	have	have	N	O
calcitonin	VBN	calcitonin	calcitonin	calcitonin	Y	O
values	NNS	values	value	valu	N	O
50	CD	50	50	50	N	O
ng	NNS	ng	ng	ng	N	O
L.	NNP	l.	l.	l.	N	O

If	IN	if	if	if	N	O
serum	JJ	serum	serum	serum	N	O
calcitonin	NN	calcitonin	calcitonin	calcitonin	Y	O
is	VBZ	is	is	is	N	O
measured	VBN	measured	measured	measur	N	O
and	CC	and	and	and	N	O
found	VBN	found	found	found	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
elevated	VBN	elevated	elevated	elev	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
further	RB	further	further	further	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
nodules	NNS	nodules	nodule	nodul	N	O
noted	VBN	noted	noted	note	N	O
on	IN	on	on	on	N	O
physical	JJ	physical	physical	physic	N	O
examination	NN	examination	examination	examin	N	O
or	CC	or	or	or	N	O
neck	NN	neck	neck	neck	N	O
imaging	NN	imaging	imaging	imag	N	O
should	MD	should	should	should	N	O
also	RB	also	also	also	N	O
be	VB	be	be	be	N	O
further	RB	further	further	further	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Acute	NNP	acute	acute	acut	N	O
Pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
acute	NN	acute	acute	acut	N	B-AdverseReaction
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
8	CD	8	8	8	N	O
Phase	NNP	phase	phase	phase	N	O
III	NNP	iii	iii	iii	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)]	NN	)]	)]	)]	N	O
,	,	,	,	,	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
adjudicated	VBD	adjudicated	adjudicated	adjud	N	O
as	IN	as	a	as	N	O
likely	RB	likely	likely	like	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
therapy	VB	therapy	therapy	therapi	N	O
occurred	PRP	occurred	occurred	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
of	IN	of	of	of	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
365	CD	365	365	365	N	O
[	NN	[	[	[	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
])	NN	])	])	])	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
of	IN	of	of	of	N	O
468	CD	468	468	468	N	O
[	JJ	[	[	[	N	O
0%	CD	0%	0%	0%	N	O
])	NN	])	])	])	N	O
or	CC	or	or	or	N	O
active	JJ	active	active	activ	N	O
comparators	NNS	comparators	comparators	compar	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
of	IN	of	of	of	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
065	CD	065	065	065	N	O
[	NN	[	[	[	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
])	NN	])	])	])	N	O
.	.	.	.	.	N	O

After	IN	after	after	after	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
,	,	,	,	,	N	O
observe	NN	observe	observe	observ	N	O
patients	NNS	patients	patient	patient	N	O
carefully	RB	carefully	carefully	care	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
persistent	NN	persistent	persistent	persist	N	O
severe	JJ	severe	severe	sever	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	O
pain	NN	pain	pain	pain	Y	O
,	,	,	,	,	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
radiating	VBG	radiating	radiating	radiat	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
back	NN	back	back	back	N	O
and	CC	and	and	and	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
or	CC	or	or	or	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
accompanied	VBN	accompanied	accompanied	accompani	N	O
by	IN	by	by	by	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
is	VBZ	is	is	is	N	O
suspected	VBN	suspected	suspected	suspect	N	O
,	,	,	,	,	N	O
promptly	RB	promptly	promptly	promptli	N	O
discontinue	VBZ	discontinue	discontinue	discontinu	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
is	VBZ	is	is	is	N	O
confirmed	VBN	confirmed	confirmed	confirm	N	O
,	,	,	,	,	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
restarted	VBN	restarted	restarted	restart	N	O
.	.	.	.	.	N	O

TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
to	TO	to	to	to	N	O
determine	VB	determine	determine	determin	N	O
whether	IN	whether	whether	whether	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
other	JJ	other	other	other	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
therapies	NNS	therapies	therapy	therapi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Hypoglycemia	NNP	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
with	IN	with	with	with	N	O
Concomitant	NNP	concomitant	concomitant	concomit	N	O
Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
Secretagogues	NNP	secretagogues	secretagogues	secretagogu	N	O
or	CC	or	or	or	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
is	VBZ	is	is	is	N	O
increased	VBN	increased	increased	increas	N	O
when	WRB	when	when	when	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
insulin	NN	insulin	insulin	insulin	Y	O
secretagogues	NNS	secretagogues	secretagogues	secretagogu	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
sulfonylureas	JJ	sulfonylureas	sulfonylurea	sulfonylurea	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
insulin	NN	insulin	insulin	insulin	Y	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
a	DT	a	a	a	N	O
lower	JJR	lower	lower	lower	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
sulfonylurea	NN	sulfonylurea	sulfonylurea	sulfonylurea	N	O
or	CC	or	or	or	N	O
insulin	NN	insulin	insulin	insulin	Y	O
to	TO	to	to	to	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
setting	NN	setting	setting	set	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O

Across	IN	across	across	across	N	O
8	CD	8	8	8	N	O
Phase	NNP	phase	phase	phase	N	O
III	NNP	iii	iii	iii	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)]	NN	)]	)]	)]	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
with	IN	with	with	with	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
occur	VBP	occur	occur	occur	N	O
,	,	,	,	,	N	O
discontinue	VBP	discontinue	discontinue	discontinu	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
;	:	;	;	;	N	O
treat	NN	treat	treat	treat	N	O
promptly	RB	promptly	promptly	promptli	N	O
per	IN	per	per	per	N	O
standard	NN	standard	standard	standard	N	O
of	IN	of	of	of	N	O
care	NN	care	care	care	N	O
and	CC	and	and	and	N	O
monitor	NN	monitor	monitor	monitor	N	O
until	IN	until	until	until	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
resolve	VBP	resolve	resolve	resolv	N	O
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4.2	CD	4.2	4.2	4.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Renal	JJ	renal	renal	renal	N	O
Impairment	NN	impairment	impairment	impair	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
GLP	NNP	glp	glp	glp	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
1	CD	1	1	1	N	I-DrugClass
receptor	NN	receptor	receptor	receptor	N	I-DrugClass
agonists	NNS	agonists	agonist	agonist	N	I-DrugClass
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
and	CC	and	and	and	N	O
worsening	NN	worsening	worsening	worsen	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
chronic	JJ	chronic	chronic	chronic	N	I-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
require	VB	require	require	requir	N	O
hemodialysis	NN	hemodialysis	hemodialysis	hemodialysi	Y	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
without	IN	without	without	without	N	O
known	VBN	known	known	known	N	O
underlying	JJ	underlying	underlying	underli	N	O
renal	JJ	renal	renal	renal	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
reported	JJ	reported	reported	report	N	O
events	NNS	events	event	event	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
experienced	VBN	experienced	experienced	experienc	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.3	CD	14.3	14.3	14.3	N	O
)]	NN	)]	)]	)]	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
such	JJ	such	such	such	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	O
as	IN	as	a	as	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
declined	VBD	declined	declined	declin	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VB	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.6	CD	8.6	8.6	8.6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
may	MD	may	may	may	N	O
worsen	VB	worsen	worsen	worsen	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
,	,	,	,	,	N	O
use	NN	use	use	use	N	O
caution	NN	caution	caution	caution	N	O
when	WRB	when	when	when	N	O
initiating	NN	initiating	initiating	initi	N	O
or	CC	or	or	or	N	O
escalating	VBG	escalating	escalating	escal	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.6	CD	8.6	8.6	8.6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
Outcomes	NNS	outcomes	outcome	outcom	N	O

There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
no	DT	no	no	no	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
establishing	VBG	establishing	establishing	establish	N	O
conclusive	JJ	conclusive	conclusive	conclus	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
risk	NN	risk	risk	risk	N	O
reduction	NN	reduction	reduction	reduct	N	O
with	IN	with	with	with	N	O
TANZEUM	NNP	tanzeum	tanzeum	tanzeum	N	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
drug	NN	drug	drug	drug	N	O
.	.	.	.	.	N	O

